Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)

@article{Kraut2010PhaseIA,
  title={Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)},
  author={Eric H. Kraut and Christopher Rhoades and Yilong Zhang and Hao Cheng and Josephine Aimiumu and Ping Chen and James Lang and Donn C. Young and Amit Agrawal and Janet E. Dancey and Kenneth K Y Chan and Michael R Grever},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2010},
  volume={67},
  pages={579-586}
}
This phase I study determined the maximal-tolerated dose, dose-limiting toxicities, pharmacokinetics, and recommended dose of erlotinib with docetaxel. Twenty-eight patients with head and neck cancer were enrolled. Patients were orally given erlotinib (50 mg) daily plus 35 mg/m2 of docetaxel intravenously weekly × 3 every 4 weeks. Dose escalation of erlotinib was in 50-mg increments until toxicity. Pharmacokinetics were studied with LC–MS/MS, standard, and population pharmacokinetic methods… CONTINUE READING